Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial

• Published in: BMC infectious diseases Vol. 23; no. 1; pp. 33 - 8
• Main Authors: Kjellberg, Anders, Hassler, Adrian, Boström, Emil, El Gharbi, Sara, Al-Ezerjawi, Sarah, Kowalski, Jan, Rodriguez-Wallberg, Kenny A., Bruchfeld, Judith, Ståhlberg, Marcus, Nygren-Bonnier, Malin, Runold, Michael, Lindholm, Peter
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.01.2023; BioMed Central; BMC
• Subjects: Age; Chronic fatigue syndrome; Clinical medicine; Clinical trial; Clinical trials; Cognitive ability; Compliance; Confidence intervals; Coronaviruses; Cough; COVID-19; COVID-19 - therapy; Double-Blind Method; Health aspects; HRQoL; Humans; Hyperbaric oxygen; Hyperbaric oxygen therapy; Hyperbaric oxygenation; Hyperbaric Oxygenation - adverse effects; Hypoxia; Infectious diseases; Long COVID; Oxygen; Patient outcomes; Patients; Physical tests; Placebos; Post COVID condition; Post-Acute COVID-19 Syndrome; Quality of Life; RCT; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Treatment Outcome; Sweden; Post COVID condition; RCT; Hyperbaric oxygen; Clinical trial; HRQoL; Safety; Long COVID; HBOT

With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options...